ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
11 announcements with these filters
Alkem incorporated a Saudi Arabian joint venture subsidiary, Alkem Pharma Company LLC, on 8 November 2026. It holds 51% after subscribing SAR 38.25 lakh, about ₹9.56 Crore.
Alkem Laboratories has scheduled its Board meeting for 12 Nov 2026 to consider Q2 and H1 FY27 unaudited results. No financial figures are disclosed in this advance notice.
Alkem Laboratories appointed Dr. Amrut Naik as CEO effective November 11, 2026. The Board designated him as Key Managerial Personnel at its November 3 meeting.
Alkem informed the exchange that US FDA completed inspection of its Mandva API facility with no Form 483 observations. The clean result confirms regulatory compliance.
Alkem Laboratories has initiated a forensic audit by Grant Thornton Bharat LLP following alleged misappropriation of funds by a former employee.
Alkem Laboratories Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements. This document details the company's equity structure.
Alkem Laboratories appointed Laxmikant Tiwari and Nilesh Vartak as Senior Management Personnel effective 12 October 2026. The appointments strengthen pharmaceutical operations and supply chain leadership.
Alkem Laboratories CFO Nitin Agrawal resigned effective 30 September 2026 for new opportunities. He was also a Key Managerial Personnel of the company.
Alkem Laboratories issued a Corporate Guarantee of Euro 54.45 Million to HSBC UK Bank for a Euro 49.5 Million term loan taken by its subsidiary, Occlutech Holding.
Alkem launches NeuCeno (cenobamate), an anti-seizure medication for partial-onset seizures in adults, for the first time in India. The once-daily drug is available in six tablet strengths.
Alkem Laboratories has appointed Dr. Shubhadeep Sinha as a Senior Management Personnel, effective September 15, 2026. This appointment falls under standard senior management disclosures.